Pharmaceuticals company FDC announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Reported at Rs 58,478.71 lakh for Q4FY26, reflecting a growth of 18.89% YoY (compared to Rs 49,188.93 lakh in Q4FY25) and 25.84% QoQ (compared to Rs 46,470.77 lakh in Q3FY26). For FY26, revenue stood at Rs 2,17,093.32 lakh, an increase of 2.94% YoY compared to Rs 2,10,812.04 lakh in FY25. Net Profit After Tax: Reported at Rs 10,339.67 lakh for Q4FY26, an increase of 167.37% YoY (compared to Rs 3,867.13 lakh in Q4FY25) and 265.33% QoQ (compared to Rs 2,830.26 lakh in Q3FY26). For FY26, net profit stood at Rs 28,142.16 lakh, up 5.48% YoY from Rs 26,678.81 lakh in FY25. Standalone Financial Highlights: Revenue from Operations: Reported at Rs 56,436.37 lakh for Q4FY26, up 17.09% YoY (compared to Rs 48,200.43 lakh in Q4FY25) and 23.24% QoQ (compared to Rs 45,794.05 lakh in Q3FY26). For FY26, revenue was Rs 2,12,632.72 lakh, a growth of 2.71% YoY over Rs 2,07,011.19 lakh in FY25. Net Profit After Tax: Reported at Rs 10,707.03 lakh for Q4FY26, an increase of 122.07% YoY (compared to Rs 4,821.55 lakh in Q4FY25) and 293.83% QoQ (compared to Rs 2,718.71 lakh in Q3FY26). For FY26, net profit was Rs 28,592.34 lakh, an increase of 4.49% YoY compared to Rs 27,362.60 lakh in FY25. Business Highlights: Segment Performance: The company operates in a single segment, namely "Pharmaceuticals". Auditor Appointments: The Board approved the re-appointment of M/s. GMVP & Associates LLP as Cost Auditor for FY27. The Board approved the re-appointment of M/s. Ford, Rhodes, Parks & Co., Chartered Accountants, as the Tax Auditor for FY27. Management Appointments: The Board approved the appointment of Mr. K. Achyutanand Reddy as the Company Secretary & Compliance Officer, effective May 26, 2026. Result PDF